Durable Cancer Regression Off-treatment and Effective Re-induction Therapy with an Anti-PD-1 Antibody

PURPOSE: Results from the first-in-human phase I trial of the anti-programmed death-1 (PD-1) antibody BMS-936558 in patients with treatment-refractory solid tumors, including safety, tolerability, pharmacodynamics, and immunologic correlates, have been previously reported. Here, we provide long-term...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Lipson, Evan J., Sharfman, William H., Drake, Charles G., Wollner, Ira, Taube, Janis M., Anders, Robert A., Xu, Haiying, Yao, Sheng, Pons, Alice, Chen, Lieping, Pardoll, Drew M., Brahmer, Julie R., Topalian, Suzanne L.
Formato: Artigo
Idioma:Inglês
Publicado: 2012
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3548952/
https://ncbi.nlm.nih.gov/pubmed/23169436
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-12-2625
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares